These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

555 related articles for article (PubMed ID: 32564022)

  • 1. Retinal Layers Changes in Patients with Diabetic Macular Edema Treated with Intravitreal Anti-VEGF Agents: Long-Term Outcomes of a Spectral-Domain OCT Study.
    Chatziralli I; Kazantzis D; Theodossiadis G; Theodossiadis P; Sergentanis TN
    Ophthalmic Res; 2021; 64(2):230-236. PubMed ID: 32564022
    [TBL] [Abstract][Full Text] [Related]  

  • 2. MEASUREMENTS OF RETINAL FLUID BY OPTICAL COHERENCE TOMOGRAPHY LEAKAGE IN DIABETIC MACULAR EDEMA: A Biomarker of Visual Acuity Response to Treatment.
    Santos AR; Alves D; Santos T; Figueira J; Silva R; Cunha-Vaz JG
    Retina; 2019 Jan; 39(1):52-60. PubMed ID: 29077605
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Optical Coherence Tomography Angiography of DME and Its Association with Anti-VEGF Treatment Response.
    Lee J; Moon BG; Cho AR; Yoon YH
    Ophthalmology; 2016 Nov; 123(11):2368-2375. PubMed ID: 27613201
    [TBL] [Abstract][Full Text] [Related]  

  • 4. IMPACT OF LONG-TERM INTRAVITREAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR ON PREEXISTING MICROSTRUCTURAL ALTERATIONS IN DIABETIC MACULAR EDEMA.
    Wirth MA; Wons J; Freiberg FJ; Becker MD; Michels S
    Retina; 2018 Sep; 38(9):1824-1829. PubMed ID: 28767550
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Relationship Between Final Visual Acuity and Optical Coherence Tomography Findings in Patients with Diabetic Macular Edema Undergoing Anti-VEGF Therapy.
    Eraslan S; Yıldırım Ö; Dursun Ö; Dinç E; Orekici Temel G
    Turk J Ophthalmol; 2020 Jun; 50(3):163-168. PubMed ID: 32631004
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dril Influences Short-term Visual Outcome after Intravitreal Corticosteroid Injection for Refractory Diabetic Macular Edema.
    Luís ME; Sampaio F; Costa J; Cabral D; Teixeira C; Ferreira JT
    Curr Eye Res; 2021 Sep; 46(9):1378-1386. PubMed ID: 33463388
    [No Abstract]   [Full Text] [Related]  

  • 7. Aqueous Humor Cytokines and Long-Term Response to Anti-Vascular Endothelial Growth Factor Therapy in Diabetic Macular Edema.
    Felfeli T; Juncal VR; Hillier RJ; Mak MYK; Wong DT; Berger AR; Kohly RP; Kertes PJ; Eng KT; Boyd SR; Altomare F; Giavedoni LR; Muni RH
    Am J Ophthalmol; 2019 Oct; 206():176-183. PubMed ID: 30959004
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Aqueous Humor Cytokine Levels and Anatomic Response to Intravitreal Ranibizumab in Diabetic Macular Edema.
    Hillier RJ; Ojaimi E; Wong DT; Mak MYK; Berger AR; Kohly RP; Kertes PJ; Forooghian F; Boyd SR; Eng K; Altomare F; Giavedoni LR; Nisenbaum R; Muni RH
    JAMA Ophthalmol; 2018 Apr; 136(4):382-388. PubMed ID: 29522144
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Quantitative assessment of macular contraction and vitreoretinal interface alterations in diabetic macular edema treated with intravitreal anti-VEGF injections.
    Cetin EN; Demirtaş Ö; Özbakış NC; Pekel G
    Graefes Arch Clin Exp Ophthalmol; 2018 Oct; 256(10):1801-1806. PubMed ID: 29922890
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Imaging retinal inflammatory biomarkers after intravitreal steroid and anti-VEGF treatment in diabetic macular oedema.
    Vujosevic S; Torresin T; Bini S; Convento E; Pilotto E; Parrozzani R; Midena E
    Acta Ophthalmol; 2017 Aug; 95(5):464-471. PubMed ID: 27775223
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparing the Efficacy of Bevacizumab and Ranibizumab in Patients with Diabetic Macular Edema (BRDME): The BRDME Study, a Randomized Trial.
    Vader MJC; Schauwvlieghe AME; Verbraak FD; Dijkman G; Hooymans JMM; Los LI; Zwinderman AH; Peto T; Hoyng CB; van Leeuwen R; Vingerling JR; Moll AC; van Lith-Verhoeven JJC; Dijkgraaf MGW; Schlingemann RO;
    Ophthalmol Retina; 2020 Aug; 4(8):777-788. PubMed ID: 32362552
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Association of Circulating Markers With Outcome Parameters in the Bevacizumab and Ranibizumab in Diabetic Macular Edema Trial.
    Fickweiler W; Klaassen I; Vogels IM; Hooymans JM; Wolffenbuttel BH; Los LI; Schlingemann RO;
    Invest Ophthalmol Vis Sci; 2016 Nov; 57(14):6234-6241. PubMed ID: 27842163
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Optical coherence tomography biomarkers DROL, PROS, SND, hyperreflective walls of foveal cystoid spaces as predictors of central macular thickness and visual acuity in diabetic macular edema treated with intravitreal ranibizumab.
    Sardana A; Singh K; Singh A; Singh VK
    Indian J Ophthalmol; 2024 May; 72(5):722-727. PubMed ID: 38648434
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The incidence and risk factors for the development of vitreomacular interface abnormality in diabetic macular edema treated with intravitreal injection of anti-VEGF.
    Chang CK; Cheng CK; Peng CH
    Eye (Lond); 2017 May; 31(5):762-770. PubMed ID: 28106889
    [TBL] [Abstract][Full Text] [Related]  

  • 15. ASSOCIATION OF SERUM VASOGENIC AND PROINFLAMMATORY FACTORS WITH CLINICAL RESPONSE TO ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR FOR DIABETIC MACULAR EDEMA.
    Brito PS; Costa JV; Barbosa-Matos C; Costa SM; Correia-Pinto J; Silva RM
    Retina; 2021 Feb; 41(2):345-354. PubMed ID: 32453069
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Repeated Dexamethasone Intravitreal Implant for the Treatment of Diabetic Macular Oedema Unresponsive to Anti-VEGF Therapy: Outcome and Predictive SD-OCT Features.
    Hatz K; Ebneter A; Tuerksever C; Pruente C; Zinkernagel M
    Ophthalmologica; 2018; 239(4):205-214. PubMed ID: 29402873
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Switching therapy from bevacizumab to aflibercept for the management of persistent diabetic macular edema.
    Bahrami B; Hong T; Zhu M; Schlub TE; Chang A
    Graefes Arch Clin Exp Ophthalmol; 2017 Jun; 255(6):1133-1140. PubMed ID: 28238195
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of Adding Dexamethasone to Continued Ranibizumab Treatment in Patients With Persistent Diabetic Macular Edema: A DRCR Network Phase 2 Randomized Clinical Trial.
    Maturi RK; Glassman AR; Liu D; Beck RW; Bhavsar AR; Bressler NM; Jampol LM; Melia M; Punjabi OS; Salehi-Had H; Sun JK;
    JAMA Ophthalmol; 2018 Jan; 136(1):29-38. PubMed ID: 29127949
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Behavior of SD-OCT-detected hyperreflective foci in the retina of anti-VEGF-treated patients with diabetic macular edema.
    Framme C; Schweizer P; Imesch M; Wolf S; Wolf-Schnurrbusch U
    Invest Ophthalmol Vis Sci; 2012 Aug; 53(9):5814-8. PubMed ID: 22836760
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of diabetic macular edema on peripapillary retinal nerve fiber layer thickness profiles.
    Hwang DJ; Lee EJ; Lee SY; Park KH; Woo SJ
    Invest Ophthalmol Vis Sci; 2014 May; 55(7):4213-9. PubMed ID: 24833740
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 28.